Pulse Biosciences, Inc
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems. Its platform includes the nPulse system and related disposable electrodes for use in surgical and minimally invasive procedures, with applications in cardiac arrhythmia treatment and soft-tissue ablation.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueConsole-based systems used to deliver nonthermal energy for tissue ablation.
Single-use electrodes and related consumables used with the company's platform.
Development programs for atrial fibrillation, tumors, and nodules.
Customers
The company sells into clinical end markets that use ablation technologies, especially electrophysiology, cardiac surgery, and minimally invasive surgery. Its buyers are hospitals, physicians, and procedural specialists that need devices for treating atrial fibrillation and other soft-tissue conditions. The business also depends on clinical investigators and trial sites that support product development and regulatory progress.
Buy ablation systems for atrial fibrillation procedures and value differentiated energy delivery.
Use the platform in procedural settings for cardiac and soft-tissue ablation.
Adopt the system for surgical ablation workflows where direct support and training matter.
Support trials and early clinical use of the company's product candidates.
Strategy
The company is focused on advancing its nonthermal pulsed field ablation platform into marketable products for atrial fibrillation, tumors, and nodules. A key priority is building clinical evidence and product performance that can compete against established ablation technologies while expanding sales, marketing, and support capabilities. It also relies on third-party relationships and direct sales execution to translate development progress into adoption.
Commercial success depends on turning the platform into approved, usable products.
The market is crowded and technology cycles are fast, so performance advantages matter.
Adoption in procedural medicine depends on training, relationships, and hands-on support.
Geography
Pulse Biosciences is headquartered in the United States, with corporate offices in Miami, Florida. The reports indicate a domestic and international commercialization ambition, but no country-level revenue disclosure was provided in the excerpts. Geography matters because the company must build sales, clinical, regulatory, and support capabilities across markets where ablation adoption and reimbursement can differ.
Risks
The company faces substantial product-development and commercialization risk because its platform must prove safety, efficacy, and clinical utility against larger competitors with more resources. It also faces execution risk in sales, manufacturing, and distribution, along with litigation, product liability, and insurance coverage constraints that are common in medical devices. Accounting risk is elevated by goodwill and intangible asset impairment exposure, stock-based estimates, and judgment-heavy disclosures tied to a development-stage business.
The business depends on creating marketable products for AF and other indications.
Exposure: nPulse System and future product candidates
Established ablation companies have greater resources and faster product cycles.
Exposure: AF ablation and micro-PFA markets
Medical devices can cause adverse events and trigger litigation or insurance losses.
Exposure: Manufactured products and trial-related events
Sales depend on trained reps, distributors, and direct procedural support.
Exposure: Domestic and international sales force
Accounting
Judgemental itemsThe company has goodwill and intangibles from prior acquisitions that require periodic testing.
Impact: Could create non-cash charges and reduce reported asset values
Claims from products or clinical trials require judgment on probability and magnitude.
Impact: Affects liabilities, expenses, and perceived financial strength
Ownership changes can restrict the use of pre-change tax losses.
Impact: May limit future tax benefit recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Edwards Lifesciences Corp
EW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences designs and sells structural heart therapies used to treat advanced cardiovascular disease, with a portfolio centered on transcatheter and surgical valve technologies.
Forte Biosciences, Inc.
Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Last updated: 29/04/2026